GlassScriptPhysician profile
Brandy Michelle Scott
NPI 1649338849
$3,015.57
in general payments reported to CMS, 2019-2025
20 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $397 · 2023: $820 · 2024: $740 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $859.84 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $338.72 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $247.89 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $247.02 | 2023-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $243.54 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $235.19 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Amneal Pharmaceuticals LLC | $134.93 | 2025 | Unithroid |
| Glaxosmithkline, LLC. | $132.71 | 2022-2024 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $81.62 | 2022-2024 | Trintellix |
| Exact Sciences Corporation | $73.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $70.08 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $67.63 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $56.58 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.27 | 2022 | |
| Inspire Medical Systems, INC. | $43.66 | 2025 | Inspire |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $39.92 | 2024-2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $35.92 | 2024 | Voquezna |
| Astellas Pharma US INC | $32.13 | 2023 | Veozah |
| Medtronic, INC. | $16.65 | 2024 | Kyphon Express II Kyphopak Tray |
| Pfizer INC. | $13.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.